Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

- Abstract Presented at ASCO Gastrointestinal Cancers Satellite Symposium -

- Positive safety data support ongoing Phase 2 trial -

SOUTH SAN FRANCISCO, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has presented safety data from a Phase 1 dose-escalation study of picoplatin, the Company's lead product candidate, at the 2008 Gastrointestinal Cancers Symposium, a meeting of the American Society of Clinical Oncology (ASCO) which is being held in Orlando, Fla.

The poster presentation included safety data from a Phase 1 study of picoplatin in combination with 5-fluorouracil (5FU) and leucovorin (LV) as a first-line treatment for metastatic colorectal cancer (mCRC). The Phase 1 study seeks to establish the maximum tolerated dose of picoplatin and provide information on the safety of picoplatin when combined with 5FU and LV for the treatment of colorectal cancer. Promising safety data observed from the study to date formed the basis for further development of picoplatin in our ongoing Phase 2 trial in mCRC.

"These study results suggest that picoplatin does not cause severe neurotoxicity, as is commonly seen in mCRC patients treated with the regimen of 5FU and LV with oxaliplatin," said Jerry McMahon, Ph.D., chairman and CEO of Poniard Pharmaceuticals. "Picoplatin has demonstrated both good tolerability and no severe neuropathies when combined with 5FU and LV. We believe picoplatin has the potential to be a preferred platinum for the treatment of colorectal and other cancer indications."

Current National Comprehensive Cancer Network (NCCN) guidelines encourage the discontinuation of FOLFOX (5FU an
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Fla. , May 29, 2015  Excite Medical ... in 2007.  Over the years, Excite Medical, under the ... be an enduring company, with a solid track record ... and growing client and distributor base.  ... success of Excite Medical has been possible, in large ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 Research ... of the "North America MRI Market - Growth, ... their offering. The North American MRI systems ... billion in 2014 to $1.58 billion by 2020 with ... systems are of three types namely, the open system, ...
(Date:5/29/2015)... PARAMUS, N.J. , May 29, 2015 A ... Business," is being presented at the Cannabis World ... in New York, NY .  Taking place ... of a dedicated day of education at the leading event ... industry. Led by Clover Leaf University, the ...
Breaking Medicine Technology:North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 2Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 3Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 4
... NEW YORK, Oct. 24, 2011 ... research report is available in its ... Ingredients (APIs) in the Americas Market ... and Generic Segments and the Pharmaceutical ...
... 24, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... health care services in China through the operations of ... hospitals and affiliated ambulatory clinics, today announced that the ... quarter and first nine months of 2011 ended September ...
Cached Medicine Technology:Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 2Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 3Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 4Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 5Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 6Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 7Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 8Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 9Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 10Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 11Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 12Chindex International, Inc. to Report Financial Results for the Third Quarter and First Nine Months of 2011 2
(Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 On ... interviewed Dr. Charles Simone and Dr. Evan Alley ... its ‘Meet the Mesothelioma Experts’ series. The interview ... on mesothelioma centers of excellence. Drs. Simone and ... director, Mary Hesdorffer, with whom they discussed the ...
(Date:5/30/2015)... 2015 Nicole Blodgett, Vice President ... Associate (DIA) designation to further her expertise in ... designed for insurance advisors, health care professionals, and ... and expertise associated with the risk and the ... is only the latest accomplishment in Nicole's journey ...
(Date:5/30/2015)... Luis Obispo, CA (PRWEB) May 30, 2015 ... Polk announced today that she is offering a free ... , The offer coincides with Disability Awareness Month, ... Happens . Industry members across the United States such ... a time to raise awareness about the possibility of ...
(Date:5/30/2015)... FL (PRWEB) May 30, 2015 A ... pieces of medical equipment from hospitals, surgery centers and ... of equipment will be sold including radiology, surgery, endoscopy, ... live auction will take place Tuesday, June 2nd starting ... Lauderdale warehouse located at 5025 North Hiatus Rd., Sunrise, ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:Centurion to Sell Surplus Medical Equipment in Online and On-site Auction 2
... most common pulmonary lung function tests. It is used to ... the effectiveness // of treatment. The patient takes a deep ... the best of their ability. The spirometer measures both the ... expelled from the lungs.New research brings to light some common ...
... research, taking smaller doses of caffeine throughout the day is found ... awake.// ,Based on their findings researchers say, most of ... few mugs of coffee or tea in the morning, or three ... in the brain will be falling as the day goes on. ...
... new type of stent that releases medication appears safe ... heart disease patients, // a process known as restenosis. ... drug everolimus. The drug acts by inhibiting cell reproduction ... similar drug-eluting stents, the one used in this study ...
... blood of healthy individuals may predict future autoimmune diseases, ... past studies and found autoantibodies (antibodies that attack the ... an illness manifests. According to a recent study ... that specific autoantibodies were detected more than four years ...
... research shows that by adding more calcium to the diet ... younger women.// ,In a study of more than 95,000 ... kidney stones over the eight years of the study. Women ... of developing kidney stones compared to women who consumed the ...
... a new weapon to their arsenal against type 2 diabetes. ... to lower the risk of diabetes in heart disease patients. ... male heart attack patients who received either a daily dose ... followed for about six years. Men taking bezafibrate, which also ...
Cached Medicine News:
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
... 2000 assays are designed ... IMMULITE 2000, a high-throughput, ... analyzer. IMMULITE 2000 offers ... and a rapidly expanding ...
... ENA Enzyme-Linked Immunosorbent Assay (ELISA) is intended for ... La, Scl-70, and Jo-1 in human sera. ... detect antibodies in a single serum specimen. ... used as an aid to the diagnosis of ...
... assays for the detection and ... extractable nuclear antigens (ENA)RNP, Sm ... Sm aid in the diagnosis ... ,RNP antibodies aid in the ...
Medicine Products: